Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

jto2 Feb. 4 at 4:34 AM

$CATX hmm that was quick — gone already. Trending after 11 PM.

0 · Reply

jto2 Feb. 4 at 4:12 AM

NET market is small, but $CATX’s Alpha RLT platform could extend to PSV359 (Solid Tumor), unlocking a $30B market. Lead VMT-Α-NET approval validates the platform, accelerating follow-on trials and boosting success probability. Acquisition value should focus on platform potential, not just NET.

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:18 AM

$CATX Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:17 AM

$CATX E2E Manufacturing !!!!!!!!!!!

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:16 AM

$CATX Solid Tumors are an Attractive Market for Radiopharmaceuticals; Potential TAM of $30 billion

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:14 AM

$CATX -Yields fewer side effects -Limits liver and kidney toxicity -Potential for broad clinical utility -Improves therapeutic window

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:13 AM

$CATX Yielding clinical results with potentially superior efficacy and safety

0 · Reply

SnackMe Feb. 4 at 1:13 AM

$CATX throw a ball straight up how many times does it come back lol . Please enjoy a visual of this groundbreaking new theory

1 · Reply

carepolice Feb. 4 at 12:16 AM

$CATX well known scammers. In 2025, former LifeSci Capital executive Robert Yedid and two associates pled guilty to a five-year insider trading scheme that generated over $500,000 in illegal profits. The scheme involved trading on confidential information regarding the firm's healthcare clients. Additionally, FINRA fined LifeSci Capital $900,000 in December 2024 for violating supervisory rules.

0 · Reply

Xanderzzzzzzz Feb. 4 at 12:13 AM

$CATX

0 · Reply

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Jan 30, 2026, 3:37 PM EST - 4 days ago

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Jan 14, 2026, 9:46 PM EST - 20 days ago

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 9, 2026, 7:00 AM EST - 25 days ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2025, 7:00 AM EST - 6 weeks ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 20, 2025, 7:00 AM EST - 2 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 11, 2025, 11:11 PM EST - 3 months ago

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:05 PM EST - 3 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 24, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 20, 2025, 5:05 PM EDT - 3 months ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 4:00 AM EDT - 3 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Sep 3, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Aug 26, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 13, 2025, 6:45 AM EDT - 6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 2, 2025, 8:53 AM EDT - 6 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Jul 24, 2025, 12:45 PM EDT - 6 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 8 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 8 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 8 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 10 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 11 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 11 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 1 year ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 1 year ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

jto2 Feb. 4 at 4:34 AM

$CATX hmm that was quick — gone already. Trending after 11 PM.

0 · Reply

jto2 Feb. 4 at 4:12 AM

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:18 AM

$CATX Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:17 AM

$CATX E2E Manufacturing !!!!!!!!!!!

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:16 AM

$CATX Solid Tumors are an Attractive Market for Radiopharmaceuticals; Potential TAM of $30 billion

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:14 AM

$CATX -Yields fewer side effects -Limits liver and kidney toxicity -Potential for broad clinical utility -Improves therapeutic window

0 · Reply

Xanderzzzzzzz Feb. 4 at 3:13 AM

$CATX Yielding clinical results with potentially superior efficacy and safety

0 · Reply

SnackMe Feb. 4 at 1:13 AM

$CATX throw a ball straight up how many times does it come back lol . Please enjoy a visual of this groundbreaking new theory

1 · Reply

carepolice Feb. 4 at 12:16 AM

0 · Reply

Xanderzzzzzzz Feb. 4 at 12:13 AM

$CATX

0 · Reply

chromeal5 Feb. 3 at 11:22 PM

$CATX Perfect Cup and Handle. Gonna take a picture and frame it.

0 · Reply

chromeal5 Feb. 3 at 11:13 PM

$CATX I like this organic rise better than what happened last week.

0 · Reply

Sw1ngb0t Feb. 3 at 10:34 PM

$INLF $GAUZ $KITT $ASTI $CATX

0 · Reply

dixiebull Feb. 3 at 10:31 PM

$IBRX see if 6 holds for break of 6.50 to 7 $LIMN we want 1.25 to hold for a move to 1.50 break nd 1.65 to 1.85 and 2 $CATX see if 5 holds for a move to 5.50/6 $PDYN we want 7.50 to hold for a chance at 8 and 8.50 $CIGL move to 5 afterhours, see if 4.25 can ohld for break of 5 to 5.50

0 · Reply

jto2 Feb. 3 at 10:10 PM

$CATX volume fading, highs pulling back—Not weakness. Low Float Lockdown. Drying up at $5. Big boys locked, weak hands out. Setup looks bullish.

0 · Reply

RunnerSignals Feb. 3 at 9:31 PM

Comeback King in action $CATX dipped then shook out the weak hands and then snapped back strong. intraday reversal + heavy volume = watching closely

0 · Reply

jto2 Feb. 3 at 9:30 PM

This also could be a clever M&A bridge. $CATX chasing $6B+ vs $200M cap? —board might flinch at 30×. A smart buyer could quietly grab a toe-hold stake ahead of a potential buyout; 20% would cost them $4.9B of $6B.

1 · Reply

Jcljack26 Feb. 3 at 9:23 PM

$CATX Closed the offering already, I have seen private offerings close this fast but a public offering closing this fast means that something good must be coming.

2 · Reply

JDinvestments Feb. 3 at 9:07 PM

$CATX up and down swing trying hard to get retail to sell worth way more $20 plus min work harder bash 🤡🤡🤡 🤣🤣🤣 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂

0 · Reply

JDinvestments Feb. 3 at 9:01 PM

$CATX 5.20 GREEN waiting on FDA STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂

1 · Reply

watchaddict Feb. 3 at 9:00 PM

$CATX ship the green close that all that matters TODAY

0 · Reply

IvyMarkets Feb. 3 at 8:27 PM

$CATX thin biotech name coiling possible asymmetry on volume

0 · Reply

Market Cap	281.74M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	8,037,900
Avg Vol	3,621,216
Day's Range	N/A - N/A
Shares Out	74.34M
Stochastic %K	74%
Beta	1.18
Analysts	Strong Sell
Price Target	$12.38